About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Krastm1Bbd
targeted mutation 1, Mariano Barbacid
MGI:3582830
Summary 31 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Krastm1Bbd/Krastm1Bbd involves: 129S1/Sv * 129X1/SvJ * C57BL/6 MGI:3582834
cn2
Krastm1Bbd/Kras+ involves: 129S1/Sv * 129X1/SvJ MGI:5508232
cn3
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Raf1tm2Bacc/Raf1tm2Bacc
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ MGI:5508357
cn4
Krastm1Bbd/Kras+
Raf1tm2Bacc/Raf1tm2Bacc
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ MGI:5508337
cn5
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Raf1tm2Bacc/Raf1tm2Bacc
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ MGI:5508355
cn6
Krastm1Bbd/Kras+
Trp53tm1Brd/Trp53+
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * FVB/N MGI:5502432
cn7
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
involves: 129S1/Sv * 129X1/SvJ MGI:5508329
cn8
Cdk4tm2.2Bbd/Cdk4tm2.1Bbd
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ MGI:4844192
cn9
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ MGI:4844193
cn10
Cdk6tm1Bbd/Cdk6tm1Bbd
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ MGI:4844194
cn11
Cdk2tm1Sgo/Cdk2tm1Sgo
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ MGI:4844195
cn12
Krastm1Bbd/Kras+
Mapk1tm1.1Hed/Mapk1tm1.1Hed
involves: 129S1/Sv * 129X1/SvJ MGI:5508239
cn13
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ MGI:5508351
cn14
Krastm1Bbd/Kras+
Map2k1tm1Chrn/Map2k1tm1Chrn
involves: 129S1/Sv * 129X1/SvJ MGI:5508242
cn15
Cdk4tm2.2Bbd/Cdk4tm2.2Bbd
Krastm1Bbd/Krastm1Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ MGI:4844188
cn16
Cdk2tm2Sgo/Cdk2tm2Sgo
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ MGI:4844189
cn17
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ MGI:4844190
cn18
Cdk4tm2.1Bbd/Cdk4tm2.1Bbd
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ MGI:4844191
cn19
Cdk4tm1.1Bbd/Cdk4+
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?
involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6 MGI:3582836
cn20
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?
involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6 MGI:3582835
cn21
Krastm1Bbd/Kras+
Mapk14tm2Nbr/Mapk14+
Polr2atm1(cre/ERT2)Bbd/Polr2a+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL MGI:3716857
cn22
Krastm1Bbd/Kras+
Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL MGI:3716855
cn23
Fntbtm1Bbd/Fntbtm1Bbd
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL MGI:3582832
cn24
Ctnnb1tm1Mmt/Ctnnb1+
Krastm1Bbd/Kras+
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 MGI:3836578
cn25
Krastm1Bbd/Kras+
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 MGI:3836577
cn26
Krastm1Bbd/Kras+
Tg(CMV-cre/ERT)1Ipc/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL MGI:3582837
cn27
Krastm1Bbd/Krastm1Bbd
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?
involves: 129S1/Sv * 129X1/SvJ * FVB/N MGI:5502430
cn28
Krastm1Bbd/Kras+
Mapk1tm1.1Hed/Mapk1tm1.1Hed
Mapk3tm1Gpg/Mapk3tm1Gpg
involves: 129/Sv * 129S1/Sv * 129X1/SvJ MGI:5508240
cn29
Krastm1Bbd/Kras+
Mapk3tm1Gpg/Mapk3tm1Gpg
involves: 129/Sv * 129S1/Sv * 129X1/SvJ MGI:5508237
cn30
Krastm1Bbd/Kras+
Map2k1tm1Chrn/Map2k1tm1Chrn
Map2k2tm1Chrn/Map2k2tm1Chrn
involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL MGI:5508244
cn31
Krastm1Bbd/Kras+
Map2k2tm1Chrn/Map2k2tm1Chrn
involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL MGI:5508243


Genotype
MGI:3582834
hm1
Allelic
Composition
Krastm1Bbd/Krastm1Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• homozygous embryos die at midgestation similar to Krastm1Tyi




Genotype
MGI:5508232
cn2
Allelic
Composition
Krastm1Bbd/Kras+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre)

mortality/aging
• 50% survival at 40 weeks of age following intratracheal instillation of Ad-Cre
• following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre), 50% of mice die by 40 weeks

tumorigenesis
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre)

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:172200




Genotype
MGI:5508357
cn3
Allelic
Composition
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Raf1tm2Bacc/Raf1tm2Bacc
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Sva mutation (1 available); any Braf mutation (27 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
Raf1tm2Bacc mutation (0 available); any Raf1 mutation (95 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• primary mouse embryonic fibroblasts exposed to 4OHT for 5 days to activate cre/ERT2 recombinase exhibit decreased proliferation that is similar to that in single Kras mutants without further additive effects




Genotype
MGI:5508337
cn4
Allelic
Composition
Krastm1Bbd/Kras+
Raf1tm2Bacc/Raf1tm2Bacc
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Raf1tm2Bacc mutation (0 available); any Raf1 mutation (95 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre), mice show 50% survival at 63 weeks compared to 38 weeks in single Kras heterozygous controls, indicating an 83% increase in survival

tumorigenesis
• tumor burden is reduced compared to single Kras heterozygotes; tumors that are found express Raf1




Genotype
MGI:5508355
cn5
Allelic
Composition
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Raf1tm2Bacc/Raf1tm2Bacc
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
Raf1tm2Bacc mutation (0 available); any Raf1 mutation (95 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• primary mouse embryonic fibroblasts exposed to 4OHT for 5 days to activate cre/ERT2 recombinase exhibit decreased proliferation compared to single Kras heterozygotes




Genotype
MGI:5502432
cn6
Allelic
Composition
Krastm1Bbd/Kras+
Trp53tm1Brd/Trp53+
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?
Genetic
Background
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Tg(Cela1-tTA)#Eps mutation (0 available)
Tg(tetO-cre)3Jig mutation (0 available)
Trp53tm1Brd mutation (6 available); any Trp53 mutation (147 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• all mice develop moderately to poorly differentiated pancreatic ductal adenocarcinomas, peritoneal explants, and perineural extensions

mortality/aging
• 50% mortality by 6 months of age
• 100% mortality by 1 year of age

tumorigenesis
• all mice develop moderately to poorly differentiated pancreatic ductal adenocarcinomas, peritoneal explants, and perineural extensions
• metastases develop affecting liver, diaphragm, lungs, lymph nodes, and spleen

Mouse Models of Human Disease
OMIM ID Ref(s)
Pancreatic Cancer 260350 J:119988




Genotype
MGI:5508329
cn7
Allelic
Composition
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Sva mutation (1 available); any Braf mutation (27 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre); tumor burden in similar to that seen in single Kras heterozygotes

mortality/aging
• following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre), mice show 50% survival at 41.5 weeks compared to 40 weeks in single Kras heterozygous controls, indicating similar survival

tumorigenesis
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre); tumor burden in similar to that seen in single Kras heterozygotes




Genotype
MGI:4844192
cn8
Allelic
Composition
Cdk4tm2.2Bbd/Cdk4tm2.1Bbd
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk4tm2.1Bbd mutation (0 available); any Cdk4 mutation (37 available)
Cdk4tm2.2Bbd mutation (0 available); any Cdk4 mutation (37 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Krastm2Bbd mutation (0 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• tamoxifen-treated mice infected with a flp-expressing adenovirus exhibit decreased proliferation and early senescence of tumor cells compared with tamoxifen and infected with GFP-expressing adenovirus
• tamoxifen-treated mice infected with a flp-expressing adenovirus exhibit reduced lesions compared to in mice treated with tamoxifen and infected with GFP-expressing adenovirus
• in tamoxifen-treated mice as in similarly treated Krastm1Bbd/Krastm2Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice

cellular
• tamoxifen-treated mice infected with a flp-expressing adenovirus exhibit early senescence of tumor cells compared with tamoxifen and infected with GFP-expressing adenovirus
• tamoxifen-treated mice infected with a flp-expressing adenovirus exhibit decreased proliferation of tumor cells compared with tamoxifen and infected with GFP-expressing adenovirus




Genotype
MGI:4844193
cn9
Allelic
Composition
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• in mice treated with tamoxifen at weaning

mortality/aging
• the mean lifespan of mice treated tamoxifen is 34-42 weeks

tumorigenesis
• in mice treated with tamoxifen at weaning
• in mice treated with tamoxifen at weaning

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer Susceptibility 3; LNCR3 612571 J:161780




Genotype
MGI:4844194
cn10
Allelic
Composition
Cdk6tm1Bbd/Cdk6tm1Bbd
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk6tm1Bbd mutation (1 available); any Cdk6 mutation (16 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• in mice treated with tamoxifen at weaning

mortality/aging
• 50% of tamoxifen-treated mice survive at 40 weeks

tumorigenesis
• in mice treated with tamoxifen at weaning
• in mice treated with tamoxifen at weaning

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer Susceptibility 3; LNCR3 612571 J:161780




Genotype
MGI:4844195
cn11
Allelic
Composition
Cdk2tm1Sgo/Cdk2tm1Sgo
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk2tm1Sgo mutation (1 available); any Cdk2 mutation (9 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice treated tamoxifen at weaning exhibit an increase in lifespan of 8 weeks (42 weeks) compared with similarly treated Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd littermates (34 weeks)

tumorigenesis
• tamoxifen-treated mice exhibit reduced tumor burden compared with similarly treated Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice




Genotype
MGI:5508239
cn12
Allelic
Composition
Krastm1Bbd/Kras+
Mapk1tm1.1Hed/Mapk1tm1.1Hed
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Mapk1tm1.1Hed mutation (0 available); any Mapk1 mutation (23 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre); tumor burden in similar to that seen in single Kras heterozygotes

mortality/aging
• 50% survival at 34.9 weeks versus 31.2 weeks in single Kras mutants following intratracheal instillation of Ad-Cre, indicating a 16% increase in survival

tumorigenesis
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre); tumor burden in similar to that seen in single Kras heterozygotes




Genotype
MGI:5508351
cn13
Allelic
Composition
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Sva mutation (1 available); any Braf mutation (27 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• primary mouse embryonic fibroblasts exposed to 4OHT for 5 days to activate cre/ERT2 recombinase exhibit decreased proliferation compared to single Kras heterozygotes




Genotype
MGI:5508242
cn14
Allelic
Composition
Krastm1Bbd/Kras+
Map2k1tm1Chrn/Map2k1tm1Chrn
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Map2k1tm1Chrn mutation (0 available); any Map2k1 mutation (85 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre); tumor burden in similar to that seen in single Kras heterozygotes

mortality/aging
• following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre), mutants show 50% survival at 44 weeks compared to 37.5 weeks in single Kras heterozygous controls, indicating a slight 22% increase in survival

tumorigenesis
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre); tumor burden in similar to that seen in single Kras heterozygotes




Genotype
MGI:4844188
cn15
Allelic
Composition
Cdk4tm2.2Bbd/Cdk4tm2.2Bbd
Krastm1Bbd/Krastm1Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk4tm2.2Bbd mutation (0 available); any Cdk4 mutation (37 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• tamoxifen-treated mice exhibit reduced tumor burden and tumor grade compared with similarly treated Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice




Genotype
MGI:4844189
cn16
Allelic
Composition
Cdk2tm2Sgo/Cdk2tm2Sgo
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk2tm2Sgo mutation (1 available); any Cdk2 mutation (9 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Krastm2Bbd mutation (0 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• tamoxifen-treated mice exhibit an increase in lifespan compared with similarly treated Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd littermates

tumorigenesis
• tamoxifen-treated mice exhibit reduced tumor burden and tumor grade compared with similarly treated Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice




Genotype
MGI:4844190
cn17
Allelic
Composition
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Krastm2Bbd mutation (0 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• lung tumors in tamoxifen-treated mice are more aggressive than in similarly treated Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice
• however, treatment with the Cdk4 inhibitor PD0332991 reduces tumor formation
• in mice treated with tamoxifen

mortality/aging
• 50% survival for tamoxifen-treated mice is 25 weeks compared with 42 weeks for similarly treated Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd littermates

tumorigenesis
• lung tumors in tamoxifen-treated mice are more aggressive than in similarly treated Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice
• however, treatment with the Cdk4 inhibitor PD0332991 reduces tumor formation
• in mice treated with tamoxifen

cellular
• proliferation of lung cells in tamoxifen-treated mice exhibit 8- to 10-fold greater proliferation than in Cdk4tm2.1Bbd/Cdk4tm2.1Bbd Krastm1Bbd/Krastm2Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer Susceptibility 3; LNCR3 612571 J:161780




Genotype
MGI:4844191
cn18
Allelic
Composition
Cdk4tm2.1Bbd/Cdk4tm2.1Bbd
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk4tm2.1Bbd mutation (0 available); any Cdk4 mutation (37 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Krastm2Bbd mutation (0 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• lung cells in tamoxifen-treated mice exhibit 8- to 10-fold reduction in proliferation and early senescence compared to in similarly treated Krastm1Bbd/Krastm2Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice
• tamoxifen-treated mice exhibit adenocarcinomas that are not as severe as in Krastm1Bbd/Krastm2Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice

cellular
• proliferation of lung cells in tamoxifen-treated mice exhibit 8- to 10-fold less proliferation than in similarly treated Krastm1Bbd/Krastm2Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice
• tamoxifen-treated mice exhibit increased cell replicative senescence in the lungs compared to in similarly treated Krastm1Bbd/Krastm2Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice




Genotype
MGI:3582836
cn19
Allelic
Composition
Cdk4tm1.1Bbd/Cdk4+
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk4tm1.1Bbd mutation (0 available); any Cdk4 mutation (37 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Tg(CMV-cre)1Cgn mutation (4 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system

respiratory system
• latency to develop lung adenomas is significantly shorter compared to double mutants wild-type for Cdk4; however development of tumors characteristic of Cdk4tm1.1Bbd mutant mice is not accelerated

tumorigenesis
• latency to develop lung adenomas is significantly shorter compared to double mutants wild-type for Cdk4; however development of tumors characteristic of Cdk4tm1.1Bbd mutant mice is not accelerated
• histiocytic sarcoma and other sarcomas are seen
• anal papillomas are seen

digestive/alimentary system
• focal metaplasia in the pancreatic ducts consisting of tall columnar cells with abundant apical mucin resembling gastric surface epithelial cells

endocrine/exocrine glands
• focal metaplasia in the pancreatic ducts consisting of tall columnar cells with abundant apical mucin resembling gastric surface epithelial cells




Genotype
MGI:3582835
cn20
Allelic
Composition
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Tg(CMV-cre)1Cgn mutation (4 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• double mutants develop breathing difficulties after 7 - 8 months of age
• frequent embryonic lethality; however, a significant number of double mutants survive

tumorigenesis
• a large spectrum of multifocal lesions are seen in the lung including; small patches of bronchiolo-alveolar hyperplasias to large bronchiolo-alveolar adenomas that compress adjacent lung structures and appear to derive from type II pneumocytes
• large bronchiolo-alveolar adenocarcinomas that compress adjacent lung structures and appear to derive from type II pneumocytes
• histiocytic sarcoma and other sarcomas seen in 2 out of 20 and 3 out of 20 double mutants, respectively
• anal papillomas seen in 3 out of 20 double mutants

cellular
• MEFs expressing the oncogenic protein do not undergo proliferative senescence and proliferate continuously as immortal cells

respiratory system
• a large spectrum of multifocal lesions are seen in the lung including; small patches of bronchiolo-alveolar hyperplasias to large bronchiolo-alveolar adenomas that compress adjacent lung structures and appear to derive from type II pneumocytes
• large bronchiolo-alveolar adenocarcinomas that compress adjacent lung structures and appear to derive from type II pneumocytes
• double mutants develop breathing difficulties after 7 - 8 months of age




Genotype
MGI:3716857
cn21
Allelic
Composition
Krastm1Bbd/Kras+
Mapk14tm2Nbr/Mapk14+
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Mapk14tm2Nbr mutation (0 available); any Mapk14 mutation (19 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• by 24 weeks, mice develop tumors in lungs
• at 4 weeks after 5-hydroxytamoxifen treatment, a few small adenomas are observed in some animals

mortality/aging
• mice live up to 40 weeks

tumorigenesis
• by 24 weeks, mice develop tumors in lungs
• at 4 weeks after 5-hydroxytamoxifen treatment, a few small adenomas are observed in some animals
• by 24 weeks, mice develop tumors in the thymus




Genotype
MGI:3716855
cn22
Allelic
Composition
Krastm1Bbd/Kras+
Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Mapk14tm1Nbr mutation (0 available); any Mapk14 mutation (19 available)
Mapk14tm2Nbr mutation (0 available); any Mapk14 mutation (19 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice die before week 32 due to increased lung cancer progression

respiratory system
• lung differentiation is abnormal with increased SP-C-positive cells
• 20 weeks after treatment, lungs are increased in size
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
• adenocarcinomas are detected at 15 weeks but not in controls

tumorigenesis
• mice also have tumors in the thymus and organs such as kidney and liver by 24 weeks after treatment whereas controls only have tumors in lungs and thymus
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
• adenocarcinomas are detected at 15 weeks but not in controls




Genotype
MGI:3582832
cn23
Allelic
Composition
Fntbtm1Bbd/Fntbtm1Bbd
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Fntbtm1Bbd mutation (1 available); any Fntb mutation (215 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (36 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• after treatment with 4-hydroxy-tamoxifen for 24 weeks multiple lung adenomas develop by 7 months of age; however no difference in the latency, number, or size of tumors was seen compared to double mutants wild-type for Fntb
• after treatment with 4-hydroxy-tamoxifen for 24 weeks multiple lung adenocarcinomas develop by 7 months of age; however no difference in the latency, number, or size of tumors was seen compared to double mutants wild-type for Fntb

tumorigenesis
• after treatment with 4-hydroxy-tamoxifen for 24 weeks multiple lung adenomas develop by 7 months of age; however no difference in the latency, number, or size of tumors was seen compared to double mutants wild-type for Fntb
• after treatment with 4-hydroxy-tamoxifen for 24 weeks multiple lung adenocarcinomas develop by 7 months of age; however no difference in the latency, number, or size of tumors was seen compared to double mutants wild-type for Fntb




Genotype
MGI:3836578
cn24
Allelic
Composition
Ctnnb1tm1Mmt/Ctnnb1+
Krastm1Bbd/Kras+
Tg(Pbsn-cre)4Prb/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ctnnb1tm1Mmt mutation (0 available); any Ctnnb1 mutation (26 available)
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Tg(Pbsn-cre)4Prb mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice die prior to day 300

reproductive system
• mice exhibit keratinized squamous metaplasia in the bulbourethral gland unlike wild-type mice
• all mice develop diffuse, locally invasive carcinomas in the prostate that develop from solid or sheet-like proliferation with occasional rosette structures, nuclear atypia, apoptotic bodies, and mitosis unlike in wild-type mice

tumorigenesis
• all mice develop diffuse, locally invasive carcinomas in the prostate that develop from solid or sheet-like proliferation with occasional rosette structures, nuclear atypia, apoptotic bodies, and mitosis unlike in wild-type mice

renal/urinary system
• mice exhibit keratinized squamous metaplasia in the urethral gland unlike wild-type mice

endocrine/exocrine glands
• mice exhibit keratinized squamous metaplasia in the bulbourethral gland unlike wild-type mice
• mice exhibit keratinized squamous metaplasia in the urethral gland unlike wild-type mice
• all mice develop diffuse, locally invasive carcinomas in the prostate that develop from solid or sheet-like proliferation with occasional rosette structures, nuclear atypia, apoptotic bodies, and mitosis unlike in wild-type mice




Genotype
MGI:3836577
cn25
Allelic
Composition
Krastm1Bbd/Kras+
Tg(Pbsn-cre)4Prb/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Tg(Pbsn-cre)4Prb mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• at 200 days, 100% of mice exhibit atypical hypoplasia unlike wild-type mice
• at 500 days, 93% of mice exhibit atypical hypoplasia unlike wild-type mice
• at 200 days, 67% of mice develop prostate intraepithelial neoplasia that display foci of small solid and cribiform intraluminal proliferation of atypical cells and nuclear atypia unlike wild-type mice
• at 500 days, 60% of mice exhibit prostate intraepithelial neoplasia unlike in wild-type mice

tumorigenesis
• at 200 days, 67% of mice develop prostate intraepithelial neoplasia that display foci of small solid and cribiform intraluminal proliferation of atypical cells and nuclear atypia unlike wild-type mice
• at 500 days, 60% of mice exhibit prostate intraepithelial neoplasia unlike in wild-type mice

endocrine/exocrine glands
• at 200 days, 100% of mice exhibit atypical hypoplasia unlike wild-type mice
• at 500 days, 93% of mice exhibit atypical hypoplasia unlike wild-type mice
• at 200 days, 67% of mice develop prostate intraepithelial neoplasia that display foci of small solid and cribiform intraluminal proliferation of atypical cells and nuclear atypia unlike wild-type mice
• at 500 days, 60% of mice exhibit prostate intraepithelial neoplasia unlike in wild-type mice

Mouse Models of Human Disease
OMIM ID Ref(s)
Prostate Cancer 176807 J:143034




Genotype
MGI:3582837
cn26
Allelic
Composition
Krastm1Bbd/Kras+
Tg(CMV-cre/ERT)1Ipc/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Tg(CMV-cre/ERT)1Ipc mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• double mutants treated with 4-hydroxy-tamoxifen at 10 days of age develop breathing difficulties after 7 - 8 months of age

tumorigenesis
• after treatment with 4-hydroxy-tamoxifen at 10 days of age, a large spectrum of multifocal lesions are seen in the lung at 7-8 months of age including; small patches of bronchiolo-alveolar hyperplasias to large bronchiolo-alveolar adenomas that compress adjacent lung structures and appear to derive from type II pneumocytes
• after treatment with 4-hydroxy-tamoxifen at 10 days of age, at 7-8 months of age large bronchiolo-alveolar adenocarcinomas that compress adjacent lung structures and appear to derive from type II pneumocytes are seen

cellular
• MEFs expressing the oncogenic protein do not undergo proliferative senescence and proliferate continuously as immortal cells

respiratory system
• after treatment with 4-hydroxy-tamoxifen at 10 days of age, a large spectrum of multifocal lesions are seen in the lung at 7-8 months of age including; small patches of bronchiolo-alveolar hyperplasias to large bronchiolo-alveolar adenomas that compress adjacent lung structures and appear to derive from type II pneumocytes
• after treatment with 4-hydroxy-tamoxifen at 10 days of age, at 7-8 months of age large bronchiolo-alveolar adenocarcinomas that compress adjacent lung structures and appear to derive from type II pneumocytes are seen
• double mutants treated with 4-hydroxy-tamoxifen at 10 days of age develop breathing difficulties after 7 - 8 months of age

endocrine/exocrine glands
• hyperplastic Harderian gland seen in double mutants treated with 4-hydroxy-tamoxifen at 10 days of age




Genotype
MGI:5502430
cn27
Allelic
Composition
Krastm1Bbd/Krastm1Bbd
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Tg(Cela1-tTA)#Eps mutation (0 available)
Tg(tetO-cre)3Jig mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• focal morphological lesions develop in acinar and centroacinar cells at 1-3 months
• acinar to ductal metaplasias develop
• some mice develop ductal adenocarcinomas by 12 months
• properties are similar to those in human patients
• sometimes areas of non malignant hyperplasia develop

tumorigenesis
• focal morphological lesions develop in acinar and centroacinar cells at 1-3 months
• acinar to ductal metaplasias develop
• some mice develop ductal adenocarcinomas by 12 months
• properties are similar to those in human patients
• sometimes areas of non malignant hyperplasia develop
• latency is increased if gene expression is delayed by maintaining exposure to doxycycline until 10 days of age
• if doxycycline exposure continues to 2 months of age, no pancreatic abnormalities develop

Mouse Models of Human Disease
OMIM ID Ref(s)
Pancreatic Cancer 260350 J:119988




Genotype
MGI:5508240
cn28
Allelic
Composition
Krastm1Bbd/Kras+
Mapk1tm1.1Hed/Mapk1tm1.1Hed
Mapk3tm1Gpg/Mapk3tm1Gpg
Genetic
Background
involves: 129/Sv * 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Mapk1tm1.1Hed mutation (0 available); any Mapk1 mutation (23 available)
Mapk3tm1Gpg mutation (1 available); any Mapk3 mutation (11 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre), mutants show 50% survival at 63 weeks versus 48 weeks in single Kras mutants, a 40% increase in survival

tumorigenesis
• 6 months following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre), only a few tumors are observed; tumors that are found express normal levels of Mapk1




Genotype
MGI:5508237
cn29
Allelic
Composition
Krastm1Bbd/Kras+
Mapk3tm1Gpg/Mapk3tm1Gpg
Genetic
Background
involves: 129/Sv * 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Mapk3tm1Gpg mutation (1 available); any Mapk3 mutation (11 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre); tumor burden in similar to that seen in single Kras heterozygotes

mortality/aging
• 50% survival at 46.3 weeks of age is seen following intratracheal instillation of Ad-Cre, a 20% increase in survival compared to single Kras mutants

tumorigenesis
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre); tumor burden in similar to that seen in single Kras heterozygotes




Genotype
MGI:5508244
cn30
Allelic
Composition
Krastm1Bbd/Kras+
Map2k1tm1Chrn/Map2k1tm1Chrn
Map2k2tm1Chrn/Map2k2tm1Chrn
Genetic
Background
involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Map2k1tm1Chrn mutation (0 available); any Map2k1 mutation (85 available)
Map2k2tm1Chrn mutation (0 available); any Map2k2 mutation (14 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• Ad-Cre treated mice show 50% survival at 57 weeks of age compared to 33 weeks of age in single Kras heterozygous controls, indicating an almost 100% increase in survival

tumorigenesis
• 6 months following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre), only a few tumors are observed; tumors that are present carry unrecombined Map2k1 alleles and express normal levels of Map2k1




Genotype
MGI:5508243
cn31
Allelic
Composition
Krastm1Bbd/Kras+
Map2k2tm1Chrn/Map2k2tm1Chrn
Genetic
Background
involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (32 available)
Map2k2tm1Chrn mutation (0 available); any Map2k2 mutation (14 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre); tumor burden in similar to that seen in single Kras heterozygotes

mortality/aging
• Ad-Cre treated mutants show 50% survival at 52 weeks compared to 45 weeks in single Kras heterozygous controls, indicating a slight 19% increase in survival

tumorigenesis
• mice develop non-small cell lung carcinoma following intratracheal instillation of adenovirus expressing Cre-recombinase (Ad-Cre); tumor burden in similar to that seen in single Kras heterozygotes





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
04/26/2016
MGI 6.03
The Jackson Laboratory